Radiographic Contrast Agent Nephropathy Clinical Trial
Official title:
The Effect of N-Acetyl Cystein in Preventing Contrast Induced Nephropathy: A Double Blind Double Dummy Randomized Controlled Trial
There are many controversies about the role of N-Acetyl Cystein in preventing of contrast nephropathy. These contradictory results may be due to different criteria for patients' selection, different end points, different type and dose of N-Acetyl Cystein administration and finally different prophylactic measures other than N-Acetyl Cystein. The investigators try to enroll a double blind double dummy study with a good power to compare the effect of this drug both in the form of oral and intravenous against the placebo in preventing the contrast nephropathy in the patients whom undergo coronary angiography/angioplasty.
Contrast Nephropathy is the third cause of acute kidney injury in hospitalized patients. The morbidity and mortality of this disorder is considerable. There is no treatment for this condition and all measures should be taken into account to prevent this complication. Among the all prophylactic measures hydration and the dose ant type of contrast are the only factors that have been proved to be effective in preventing contrast nephropathy. N-Acetyl Cystein is an antioxidant agents that may be effective in different aspects of medicine, but it,s use in this condition is controversial. While some studies showed it is effective in prevention of contrast nephropathy, others showed no benefit. Different studies used different dose and route of administration. So more clinical trials with good power are needed to compare different oral Vs IV administration of the drug in a randomized double blinded clinical trial. In this study we allocate the eligible patients with chronic kidney diseases stages 2 to 4 to three groups. Oral N-Acetyl Cystein group, IV N-Acetyl Cystein group, placebo group. All group will be matched according to stages of chronic kidney diseases, diabetes, anemia, heart failure, age and sex. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00540904 -
Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate
|
Phase 2 | |
| Recruiting |
NCT00584350 -
Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP
|
Phase 4 | |
| Completed |
NCT02137863 -
Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy
|
Phase 4 | |
| Completed |
NCT01866800 -
The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVI
|
Phase 4 | |
| Active, not recruiting |
NCT01778140 -
Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System
|
N/A | |
| Completed |
NCT02483143 -
NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial
|
Phase 4 | |
| Completed |
NCT01525888 -
Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy
|
N/A | |
| Recruiting |
NCT02643706 -
Relationship Between ALDH2 and CIN
|
N/A | |
| Terminated |
NCT01168024 -
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
|
Phase 3 | |
| Completed |
NCT02643602 -
Does Bicarbonate in Addition to Theophylline Reduce CIN?
|
N/A | |
| Recruiting |
NCT02029820 -
RenalGuard System for Prevention of Contrast Induced Nephropathy
|
Phase 3 | |
| Terminated |
NCT01654328 -
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
|
N/A |